Melanie Cree
Concepts (425)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Ovary Syndrome | 27 | 2026 | 180 | 12.390 |
Why?
| | Insulin Resistance | 63 | 2026 | 1241 | 10.160 |
Why?
| | Diabetes Mellitus, Type 2 | 34 | 2026 | 2583 | 3.970 |
Why?
| | Mitochondria, Muscle | 11 | 2024 | 121 | 3.480 |
Why?
| | Obesity | 31 | 2026 | 3077 | 3.420 |
Why?
| | Blood Glucose | 40 | 2026 | 2327 | 3.180 |
Why?
| | Pediatric Obesity | 13 | 2026 | 637 | 2.930 |
Why?
| | Glucose Intolerance | 11 | 2021 | 142 | 2.720 |
Why?
| | Muscle, Skeletal | 32 | 2026 | 1795 | 2.530 |
Why?
| | Glucose Clamp Technique | 16 | 2023 | 199 | 2.480 |
Why?
| | Metformin | 10 | 2021 | 318 | 2.190 |
Why?
| | Insulin | 29 | 2026 | 2507 | 2.160 |
Why?
| | Glucose Tolerance Test | 21 | 2025 | 361 | 2.160 |
Why?
| | Adolescent | 86 | 2026 | 22428 | 2.150 |
Why?
| | Fatty Liver | 7 | 2026 | 251 | 2.140 |
Why?
| | Liver | 13 | 2026 | 1887 | 2.030 |
Why?
| | Testosterone | 7 | 2024 | 419 | 2.000 |
Why?
| | Fasting | 7 | 2024 | 277 | 1.940 |
Why?
| | Triglycerides | 9 | 2022 | 520 | 1.830 |
Why?
| | Hyperandrogenism | 3 | 2024 | 21 | 1.810 |
Why?
| | Fatty Acids, Nonesterified | 7 | 2018 | 158 | 1.540 |
Why?
| | Diabetes Mellitus, Type 1 | 17 | 2024 | 3890 | 1.470 |
Why?
| | Metabolic Syndrome | 3 | 2020 | 354 | 1.460 |
Why?
| | Body Mass Index | 15 | 2026 | 2438 | 1.430 |
Why?
| | Female | 108 | 2026 | 78271 | 1.370 |
Why?
| | Lipolysis | 4 | 2019 | 46 | 1.290 |
Why?
| | Adipose Tissue | 7 | 2026 | 652 | 1.290 |
Why?
| | Burns | 9 | 2010 | 377 | 1.280 |
Why?
| | Lipid Metabolism | 6 | 2019 | 527 | 1.270 |
Why?
| | Hyperinsulinism | 4 | 2019 | 113 | 1.250 |
Why?
| | Circadian Rhythm | 7 | 2025 | 514 | 1.170 |
Why?
| | Child | 52 | 2026 | 22633 | 1.170 |
Why?
| | Young Adult | 37 | 2025 | 14105 | 1.150 |
Why?
| | Humans | 130 | 2026 | 144759 | 1.110 |
Why?
| | Magnetic Resonance Spectroscopy | 9 | 2024 | 630 | 1.080 |
Why?
| | Glycerol | 6 | 2023 | 90 | 1.080 |
Why?
| | Cross-Sectional Studies | 22 | 2024 | 5868 | 1.070 |
Why?
| | Oxidative Phosphorylation | 4 | 2019 | 210 | 1.060 |
Why?
| | Exercise | 14 | 2026 | 2201 | 1.020 |
Why?
| | Body Composition | 8 | 2026 | 706 | 0.980 |
Why?
| | Glucose | 10 | 2023 | 1047 | 0.950 |
Why?
| | Hypoglycemic Agents | 9 | 2019 | 1387 | 0.920 |
Why?
| | Cardiovascular Diseases | 7 | 2025 | 2168 | 0.910 |
Why?
| | Case-Control Studies | 16 | 2025 | 3604 | 0.900 |
Why?
| | Insulin-Secreting Cells | 6 | 2020 | 388 | 0.890 |
Why?
| | Male | 81 | 2026 | 72315 | 0.860 |
Why?
| | Androgens | 2 | 2022 | 186 | 0.790 |
Why?
| | Prediabetic State | 4 | 2021 | 245 | 0.770 |
Why?
| | Sleep | 6 | 2026 | 901 | 0.760 |
Why?
| | Sleep Initiation and Maintenance Disorders | 2 | 2020 | 194 | 0.750 |
Why?
| | Transition to Adult Care | 1 | 2024 | 96 | 0.730 |
Why?
| | Gastrointestinal Microbiome | 2 | 2021 | 771 | 0.730 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2021 | 266 | 0.730 |
Why?
| | Hyperglycemia | 4 | 2021 | 375 | 0.720 |
Why?
| | Adult | 46 | 2026 | 40449 | 0.700 |
Why?
| | Adenosine Diphosphate | 2 | 2021 | 84 | 0.680 |
Why?
| | Adolescent Medicine | 1 | 2020 | 26 | 0.640 |
Why?
| | Klinefelter Syndrome | 1 | 2021 | 69 | 0.640 |
Why?
| | Desogestrel | 1 | 2020 | 46 | 0.640 |
Why?
| | Absorptiometry, Photon | 7 | 2026 | 276 | 0.630 |
Why?
| | Obesity, Morbid | 1 | 2024 | 281 | 0.630 |
Why?
| | Lipogenesis | 2 | 2019 | 62 | 0.620 |
Why?
| | Overweight | 6 | 2025 | 609 | 0.620 |
Why?
| | Isotopes | 1 | 2019 | 34 | 0.610 |
Why?
| | Inservice Training | 1 | 2020 | 117 | 0.600 |
Why?
| | Endocrinology | 1 | 2020 | 77 | 0.600 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2019 | 52 | 0.580 |
Why?
| | Gluconeogenesis | 1 | 2019 | 83 | 0.570 |
Why?
| | Adiposity | 5 | 2025 | 543 | 0.570 |
Why?
| | Energy Metabolism | 3 | 2024 | 935 | 0.560 |
Why?
| | Obesity, Abdominal | 1 | 2018 | 46 | 0.560 |
Why?
| | Gynecology | 1 | 2020 | 178 | 0.540 |
Why?
| | Mentors | 1 | 2020 | 219 | 0.540 |
Why?
| | C-Peptide | 6 | 2026 | 189 | 0.540 |
Why?
| | Interprofessional Relations | 1 | 2020 | 281 | 0.530 |
Why?
| | Fenofibrate | 2 | 2007 | 28 | 0.510 |
Why?
| | Mentoring | 1 | 2020 | 166 | 0.510 |
Why?
| | Fatty Acids | 2 | 2019 | 450 | 0.510 |
Why?
| | Depressive Disorder | 1 | 2020 | 387 | 0.500 |
Why?
| | Lipoproteins, HDL | 1 | 2017 | 101 | 0.490 |
Why?
| | Hypolipidemic Agents | 2 | 2007 | 88 | 0.490 |
Why?
| | Amino Acids | 3 | 2019 | 521 | 0.490 |
Why?
| | Oxygen Consumption | 9 | 2024 | 724 | 0.480 |
Why?
| | Biodiversity | 1 | 2020 | 426 | 0.480 |
Why?
| | Diabetic Nephropathies | 4 | 2026 | 318 | 0.470 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2025 | 88 | 0.430 |
Why?
| | Muscle Proteins | 7 | 2017 | 244 | 0.430 |
Why?
| | Severity of Illness Index | 4 | 2025 | 2925 | 0.420 |
Why?
| | Mitochondria | 5 | 2024 | 984 | 0.420 |
Why?
| | Lipoproteins | 1 | 2015 | 169 | 0.410 |
Why?
| | Gastrectomy | 2 | 2026 | 161 | 0.410 |
Why?
| | Magnetic Resonance Imaging | 8 | 2026 | 3863 | 0.410 |
Why?
| | Prognosis | 5 | 2020 | 4282 | 0.410 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 1098 | 0.400 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2025 | 300 | 0.400 |
Why?
| | Aging | 3 | 2019 | 1966 | 0.400 |
Why?
| | B-Lymphocytes | 1 | 2019 | 876 | 0.400 |
Why?
| | Bacteria | 1 | 2020 | 889 | 0.390 |
Why?
| | Cohort Studies | 9 | 2021 | 5960 | 0.390 |
Why?
| | PPAR alpha | 3 | 2007 | 54 | 0.390 |
Why?
| | Decision Making | 1 | 2020 | 975 | 0.380 |
Why?
| | Cardiorespiratory Fitness | 3 | 2024 | 72 | 0.380 |
Why?
| | Sleep Deprivation | 2 | 2025 | 206 | 0.370 |
Why?
| | Oxygen | 1 | 2018 | 995 | 0.370 |
Why?
| | Bed Rest | 2 | 2009 | 15 | 0.370 |
Why?
| | Risk Factors | 12 | 2025 | 10779 | 0.370 |
Why?
| | Follow-Up Studies | 6 | 2020 | 5408 | 0.360 |
Why?
| | Calorimetry, Indirect | 2 | 2024 | 83 | 0.350 |
Why?
| | Insulin Glargine | 3 | 2019 | 88 | 0.350 |
Why?
| | Actigraphy | 5 | 2026 | 145 | 0.330 |
Why?
| | Puberty | 3 | 2024 | 140 | 0.330 |
Why?
| | Cystic Fibrosis | 1 | 2020 | 1158 | 0.320 |
Why?
| | Hirsutism | 2 | 2021 | 11 | 0.320 |
Why?
| | Cushing Syndrome | 1 | 2009 | 10 | 0.310 |
Why?
| | Gastroplasty | 2 | 2021 | 32 | 0.310 |
Why?
| | Middle Aged | 18 | 2026 | 35875 | 0.300 |
Why?
| | Algorithms | 2 | 2021 | 1837 | 0.290 |
Why?
| | Estradiol | 3 | 2022 | 533 | 0.290 |
Why?
| | Pleural Neoplasms | 1 | 2009 | 27 | 0.290 |
Why?
| | Prospective Studies | 7 | 2020 | 7990 | 0.280 |
Why?
| | Mesothelioma | 1 | 2009 | 48 | 0.280 |
Why?
| | Retrospective Studies | 8 | 2024 | 17066 | 0.270 |
Why?
| | Melatonin | 4 | 2025 | 163 | 0.270 |
Why?
| | Protein Kinase C | 1 | 2008 | 252 | 0.250 |
Why?
| | Sex Characteristics | 3 | 2025 | 790 | 0.250 |
Why?
| | Exercise Tolerance | 4 | 2017 | 283 | 0.250 |
Why?
| | Diabetic Cardiomyopathies | 2 | 2016 | 34 | 0.240 |
Why?
| | Diabetes, Gestational | 2 | 2025 | 321 | 0.230 |
Why?
| | Janus Kinases | 1 | 2026 | 20 | 0.230 |
Why?
| | STAT Transcription Factors | 1 | 2026 | 24 | 0.230 |
Why?
| | Autoimmunity | 1 | 2012 | 926 | 0.230 |
Why?
| | Apolipoproteins B | 1 | 2025 | 47 | 0.230 |
Why?
| | Saliva | 3 | 2025 | 249 | 0.230 |
Why?
| | Abdominal Fat | 1 | 2025 | 50 | 0.230 |
Why?
| | Weight Loss | 3 | 2026 | 836 | 0.220 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2026 | 139 | 0.220 |
Why?
| | Metabolic Diseases | 1 | 2026 | 114 | 0.220 |
Why?
| | Reproducibility of Results | 8 | 2025 | 3409 | 0.220 |
Why?
| | Biological Clocks | 1 | 2025 | 49 | 0.220 |
Why?
| | Carotid Intima-Media Thickness | 3 | 2025 | 75 | 0.220 |
Why?
| | Carnitine | 3 | 2019 | 90 | 0.210 |
Why?
| | Adiponectin | 2 | 2016 | 244 | 0.210 |
Why?
| | Time Factors | 7 | 2026 | 7173 | 0.210 |
Why?
| | Lipoproteins, VLDL | 1 | 2024 | 21 | 0.210 |
Why?
| | Alanine Transaminase | 1 | 2024 | 151 | 0.210 |
Why?
| | Terminology as Topic | 1 | 2026 | 255 | 0.200 |
Why?
| | Basal Metabolism | 1 | 2024 | 62 | 0.200 |
Why?
| | Adenosine Triphosphate | 2 | 2021 | 498 | 0.200 |
Why?
| | Polysomnography | 1 | 2025 | 235 | 0.200 |
Why?
| | Muscle Contraction | 3 | 2014 | 429 | 0.200 |
Why?
| | Dyslipidemias | 1 | 2025 | 181 | 0.200 |
Why?
| | Aged | 12 | 2020 | 25913 | 0.200 |
Why?
| | Age Factors | 3 | 2020 | 3333 | 0.200 |
Why?
| | Leg | 5 | 2021 | 239 | 0.200 |
Why?
| | Endocrine System Diseases | 1 | 2023 | 35 | 0.200 |
Why?
| | Continuity of Patient Care | 1 | 2006 | 291 | 0.190 |
Why?
| | Ventricular Remodeling | 1 | 2025 | 276 | 0.190 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 212 | 0.190 |
Why?
| | Muscle Strength | 2 | 2017 | 330 | 0.190 |
Why?
| | Vascular Stiffness | 2 | 2019 | 486 | 0.190 |
Why?
| | Colorado | 5 | 2020 | 4564 | 0.190 |
Why?
| | Lipids | 4 | 2017 | 710 | 0.180 |
Why?
| | Carbon Isotopes | 4 | 2019 | 144 | 0.180 |
Why?
| | Bariatric Surgery | 1 | 2026 | 242 | 0.180 |
Why?
| | Sex Factors | 3 | 2017 | 2112 | 0.180 |
Why?
| | Double-Blind Method | 3 | 2019 | 2029 | 0.180 |
Why?
| | Biomarkers | 6 | 2019 | 4271 | 0.180 |
Why?
| | Heart | 1 | 2025 | 636 | 0.180 |
Why?
| | Phosphocreatine | 1 | 2021 | 44 | 0.170 |
Why?
| | Child, Preschool | 9 | 2022 | 11787 | 0.170 |
Why?
| | Atherosclerosis | 1 | 2025 | 409 | 0.170 |
Why?
| | Incidence | 3 | 2021 | 2879 | 0.170 |
Why?
| | Tandem Mass Spectrometry | 1 | 2024 | 576 | 0.170 |
Why?
| | Hospitalization | 2 | 2016 | 2433 | 0.170 |
Why?
| | Transgender Persons | 1 | 2024 | 191 | 0.170 |
Why?
| | Glutathione | 1 | 2023 | 375 | 0.170 |
Why?
| | Alopecia | 1 | 2021 | 37 | 0.170 |
Why?
| | Bacteroidetes | 1 | 2021 | 21 | 0.170 |
Why?
| | Sleep Wake Disorders | 2 | 2019 | 301 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2145 | 0.170 |
Why?
| | Body Weight | 2 | 2019 | 976 | 0.170 |
Why?
| | Contraceptive Devices, Female | 1 | 2020 | 14 | 0.160 |
Why?
| | Sex Chromosome Disorders of Sex Development | 1 | 2020 | 17 | 0.160 |
Why?
| | Ovarian Reserve | 1 | 2020 | 17 | 0.160 |
Why?
| | Drug Implants | 1 | 2020 | 83 | 0.160 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2020 | 40 | 0.160 |
Why?
| | Protein Biosynthesis | 2 | 2017 | 458 | 0.150 |
Why?
| | Prednisolone | 1 | 2019 | 66 | 0.150 |
Why?
| | Glucose Metabolism Disorders | 1 | 2019 | 11 | 0.150 |
Why?
| | Arginine | 2 | 2019 | 262 | 0.150 |
Why?
| | Sitagliptin Phosphate | 1 | 2019 | 31 | 0.150 |
Why?
| | Liraglutide | 1 | 2019 | 32 | 0.150 |
Why?
| | Amino Acids, Essential | 2 | 2009 | 13 | 0.150 |
Why?
| | Linear Models | 3 | 2014 | 854 | 0.150 |
Why?
| | Device Removal | 1 | 2020 | 143 | 0.150 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2019 | 147 | 0.150 |
Why?
| | Uromodulin | 1 | 2019 | 22 | 0.150 |
Why?
| | Virilism | 1 | 2019 | 6 | 0.150 |
Why?
| | Menstruation Disturbances | 1 | 2019 | 13 | 0.150 |
Why?
| | Aorta | 2 | 2019 | 429 | 0.150 |
Why?
| | Waist Circumference | 1 | 2019 | 139 | 0.150 |
Why?
| | Physicians, Women | 1 | 2020 | 88 | 0.150 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2019 | 51 | 0.150 |
Why?
| | Diastole | 1 | 2019 | 143 | 0.140 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 46 | 0.140 |
Why?
| | Contraceptives, Oral | 1 | 2019 | 37 | 0.140 |
Why?
| | Withholding Treatment | 1 | 2019 | 80 | 0.140 |
Why?
| | Spironolactone | 1 | 2019 | 39 | 0.140 |
Why?
| | United States | 3 | 2021 | 15966 | 0.140 |
Why?
| | Respiratory Function Tests | 1 | 2020 | 547 | 0.140 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2115 | 0.140 |
Why?
| | Cardiotonic Agents | 1 | 2018 | 95 | 0.140 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 558 | 0.140 |
Why?
| | Deuterium | 3 | 2015 | 100 | 0.140 |
Why?
| | Minority Groups | 1 | 2020 | 282 | 0.140 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 541 | 0.140 |
Why?
| | Career Choice | 1 | 2020 | 237 | 0.140 |
Why?
| | Cell Respiration | 1 | 2018 | 107 | 0.140 |
Why?
| | Intra-Abdominal Fat | 1 | 2018 | 100 | 0.130 |
Why?
| | Wakefulness | 1 | 2019 | 169 | 0.130 |
Why?
| | Spasms, Infantile | 1 | 2019 | 136 | 0.130 |
Why?
| | Peer Group | 1 | 2020 | 257 | 0.130 |
Why?
| | Alberta | 2 | 2009 | 26 | 0.130 |
Why?
| | Universities | 1 | 2020 | 452 | 0.130 |
Why?
| | Phosphorus Isotopes | 1 | 2017 | 8 | 0.130 |
Why?
| | Feces | 1 | 2021 | 513 | 0.130 |
Why?
| | Erythrocytes | 1 | 2023 | 757 | 0.130 |
Why?
| | Blood Vessels | 1 | 2018 | 171 | 0.130 |
Why?
| | Social Media | 1 | 2020 | 171 | 0.130 |
Why?
| | Hindlimb | 1 | 2017 | 131 | 0.130 |
Why?
| | Child Behavior | 1 | 2019 | 236 | 0.130 |
Why?
| | Kidney | 4 | 2021 | 1495 | 0.120 |
Why?
| | Affect | 1 | 2019 | 318 | 0.120 |
Why?
| | Human Development | 1 | 2016 | 21 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2020 | 354 | 0.120 |
Why?
| | Bone Density | 1 | 2020 | 482 | 0.120 |
Why?
| | Placental Insufficiency | 1 | 2017 | 125 | 0.120 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 556 | 0.120 |
Why?
| | Regional Blood Flow | 2 | 2016 | 514 | 0.120 |
Why?
| | Parenting | 1 | 2020 | 318 | 0.120 |
Why?
| | Prevalence | 2 | 2021 | 2834 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6048 | 0.120 |
Why?
| | Societies, Medical | 1 | 2020 | 887 | 0.120 |
Why?
| | Estrogens | 1 | 2019 | 380 | 0.120 |
Why?
| | Social Support | 1 | 2020 | 652 | 0.120 |
Why?
| | Milk Proteins | 2 | 2006 | 35 | 0.120 |
Why?
| | Leptin | 1 | 2017 | 245 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2019 | 535 | 0.110 |
Why?
| | Schools | 1 | 2018 | 453 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1047 | 0.110 |
Why?
| | Metabolome | 1 | 2019 | 384 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.110 |
Why?
| | Life Style | 2 | 2018 | 479 | 0.110 |
Why?
| | Pulse Wave Analysis | 3 | 2021 | 266 | 0.110 |
Why?
| | Phosphorus | 1 | 2014 | 99 | 0.100 |
Why?
| | Biopsy | 2 | 2008 | 1075 | 0.100 |
Why?
| | Asthma | 1 | 2006 | 1767 | 0.100 |
Why?
| | Inflammation Mediators | 1 | 2017 | 509 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2006 | 2310 | 0.100 |
Why?
| | Glomerular Filtration Rate | 4 | 2020 | 760 | 0.100 |
Why?
| | Exercise Therapy | 1 | 2018 | 473 | 0.100 |
Why?
| | Metabolomics | 1 | 2019 | 727 | 0.100 |
Why?
| | Signal Transduction | 2 | 2026 | 5226 | 0.100 |
Why?
| | Echocardiography | 1 | 2016 | 652 | 0.090 |
Why?
| | Blood Pressure | 2 | 2017 | 1769 | 0.090 |
Why?
| | Risk Assessment | 2 | 2017 | 3671 | 0.090 |
Why?
| | Ventricular Function, Left | 1 | 2016 | 541 | 0.090 |
Why?
| | Area Under Curve | 3 | 2008 | 330 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2015 | 582 | 0.090 |
Why?
| | Regression Analysis | 2 | 2025 | 1003 | 0.090 |
Why?
| | Pyruvic Acid | 2 | 2010 | 55 | 0.090 |
Why?
| | Models, Biological | 1 | 2019 | 1821 | 0.090 |
Why?
| | Fetal Growth Retardation | 1 | 2017 | 587 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1694 | 0.090 |
Why?
| | Physicians | 1 | 2020 | 939 | 0.090 |
Why?
| | Emotions | 1 | 2017 | 578 | 0.090 |
Why?
| | Hypoglycemia | 1 | 2016 | 477 | 0.080 |
Why?
| | Hypertension | 1 | 2019 | 1263 | 0.080 |
Why?
| | Creatinine | 3 | 2020 | 506 | 0.080 |
Why?
| | Disease Progression | 2 | 2022 | 2847 | 0.080 |
Why?
| | Genotype | 2 | 2025 | 1833 | 0.080 |
Why?
| | Treatment Outcome | 6 | 2019 | 11679 | 0.080 |
Why?
| | Jet Lag Syndrome | 1 | 2019 | 13 | 0.070 |
Why?
| | Acyl Coenzyme A | 2 | 2006 | 31 | 0.070 |
Why?
| | Cohort Effect | 1 | 2009 | 4 | 0.070 |
Why?
| | Internship and Residency | 1 | 2020 | 1257 | 0.070 |
Why?
| | Asbestos | 1 | 2009 | 35 | 0.070 |
Why?
| | Protein Kinase C beta | 1 | 2008 | 21 | 0.070 |
Why?
| | Palmitates | 1 | 2008 | 21 | 0.070 |
Why?
| | Hypertriglyceridemia | 1 | 2008 | 44 | 0.070 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2005 | 179 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2025 | 1985 | 0.070 |
Why?
| | Age Distribution | 1 | 2009 | 403 | 0.070 |
Why?
| | Sex Distribution | 1 | 2009 | 386 | 0.070 |
Why?
| | Muscle Cells | 1 | 2007 | 42 | 0.060 |
Why?
| | Quality Improvement | 1 | 2016 | 1289 | 0.060 |
Why?
| | Acetates | 1 | 2007 | 80 | 0.060 |
Why?
| | Albuminuria | 2 | 2020 | 190 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2005 | 594 | 0.060 |
Why?
| | Trauma Severity Indices | 1 | 2007 | 112 | 0.060 |
Why?
| | Pregnancy | 4 | 2025 | 7190 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2947 | 0.060 |
Why?
| | Peptide YY | 1 | 2026 | 25 | 0.060 |
Why?
| | Islets of Langerhans | 1 | 2012 | 833 | 0.060 |
Why?
| | Phenylalanine | 4 | 2009 | 71 | 0.060 |
Why?
| | Apolipoprotein B-100 | 1 | 2025 | 13 | 0.060 |
Why?
| | Muscular Atrophy | 1 | 2006 | 89 | 0.060 |
Why?
| | Carbon Dioxide | 1 | 2007 | 242 | 0.060 |
Why?
| | Milk | 1 | 2006 | 119 | 0.060 |
Why?
| | Animals | 8 | 2017 | 38058 | 0.060 |
Why?
| | Accelerometry | 1 | 2026 | 119 | 0.060 |
Why?
| | Caseins | 1 | 2004 | 20 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2026 | 146 | 0.050 |
Why?
| | Cystatin C | 2 | 2014 | 65 | 0.050 |
Why?
| | Self Report | 1 | 2019 | 872 | 0.050 |
Why?
| | Oxidation-Reduction | 1 | 2008 | 1087 | 0.050 |
Why?
| | Albumins | 1 | 2005 | 118 | 0.050 |
Why?
| | Critical Care | 1 | 2010 | 695 | 0.050 |
Why?
| | Consensus | 1 | 2026 | 488 | 0.050 |
Why?
| | Fibrinogen | 1 | 2005 | 177 | 0.050 |
Why?
| | Physical Exertion | 1 | 2005 | 207 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2026 | 601 | 0.050 |
Why?
| | Placebos | 2 | 2019 | 192 | 0.050 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 93 | 0.050 |
Why?
| | Stress, Physiological | 1 | 2006 | 453 | 0.050 |
Why?
| | Dietary Carbohydrates | 1 | 2003 | 151 | 0.050 |
Why?
| | Exercise Test | 3 | 2016 | 634 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2025 | 612 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2022 | 111 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 339 | 0.050 |
Why?
| | Light | 1 | 2025 | 411 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2006 | 600 | 0.040 |
Why?
| | Critical Illness | 1 | 2007 | 891 | 0.040 |
Why?
| | Gonadotropins | 1 | 2020 | 39 | 0.040 |
Why?
| | Hydroxyestrones | 1 | 2000 | 2 | 0.040 |
Why?
| | Isoflavones | 1 | 2000 | 26 | 0.040 |
Why?
| | Anti-Mullerian Hormone | 1 | 2020 | 57 | 0.040 |
Why?
| | Chromosomes, Human, X | 1 | 2020 | 76 | 0.040 |
Why?
| | Sex Chromosome Aberrations | 1 | 2020 | 69 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2020 | 60 | 0.040 |
Why?
| | Registries | 1 | 2009 | 2385 | 0.040 |
Why?
| | Parental Leave | 1 | 2020 | 27 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1886 | 0.040 |
Why?
| | Trisomy | 1 | 2020 | 78 | 0.040 |
Why?
| | Causality | 1 | 2019 | 126 | 0.040 |
Why?
| | Hormones | 1 | 2019 | 134 | 0.040 |
Why?
| | Sulfonylurea Compounds | 1 | 2019 | 51 | 0.040 |
Why?
| | Administration, Oral | 3 | 2006 | 847 | 0.040 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1560 | 0.040 |
Why?
| | Rats, Zucker | 2 | 2010 | 32 | 0.040 |
Why?
| | Anxiety | 1 | 2025 | 1109 | 0.030 |
Why?
| | Biological Transport | 2 | 2010 | 417 | 0.030 |
Why?
| | Diabetic Angiopathies | 1 | 2019 | 263 | 0.030 |
Why?
| | Magnetic Resonance Angiography | 1 | 2018 | 251 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2009 | 8265 | 0.030 |
Why?
| | Physicians, Primary Care | 1 | 2018 | 207 | 0.030 |
Why?
| | Whey Proteins | 2 | 2006 | 9 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2016 | 115 | 0.030 |
Why?
| | Depression | 1 | 2025 | 1558 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 189 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2020 | 6429 | 0.030 |
Why?
| | Sheep | 1 | 2017 | 880 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1658 | 0.030 |
Why?
| | Rabbits | 2 | 2005 | 648 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1489 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2021 | 1339 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 494 | 0.030 |
Why?
| | Infant | 2 | 2019 | 10034 | 0.030 |
Why?
| | Mothers | 1 | 2020 | 775 | 0.020 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 145 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 204 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 358 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 842 | 0.020 |
Why?
| | Diet | 1 | 2000 | 1273 | 0.020 |
Why?
| | Glucagon | 1 | 2012 | 112 | 0.020 |
Why?
| | Parents | 1 | 2020 | 1403 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1539 | 0.020 |
Why?
| | Malonyl Coenzyme A | 1 | 2010 | 5 | 0.020 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2010 | 32 | 0.020 |
Why?
| | Glycogen | 1 | 2010 | 54 | 0.020 |
Why?
| | Sciatic Nerve | 1 | 2010 | 59 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 570 | 0.020 |
Why?
| | Rats | 2 | 2010 | 5597 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 423 | 0.020 |
Why?
| | Cholesterol, VLDL | 1 | 2008 | 5 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2010 | 282 | 0.020 |
Why?
| | Lactic Acid | 1 | 2010 | 302 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 851 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 779 | 0.020 |
Why?
| | Primary Health Care | 1 | 2018 | 1733 | 0.020 |
Why?
| | Radioactive Tracers | 1 | 2007 | 4 | 0.020 |
Why?
| | Citric Acid Cycle | 1 | 2007 | 59 | 0.020 |
Why?
| | Breath Tests | 1 | 2007 | 79 | 0.020 |
Why?
| | Sodium Bicarbonate | 1 | 2007 | 47 | 0.020 |
Why?
| | Cholesterol | 1 | 2008 | 406 | 0.020 |
Why?
| | Multienzyme Complexes | 1 | 2006 | 67 | 0.020 |
Why?
| | Diglycerides | 1 | 2006 | 59 | 0.020 |
Why?
| | Palmitoylcarnitine | 1 | 2005 | 1 | 0.010 |
Why?
| | Methods | 1 | 2005 | 69 | 0.010 |
Why?
| | Carbohydrate Sequence | 1 | 2005 | 28 | 0.010 |
Why?
| | Palmitic Acid | 1 | 2005 | 42 | 0.010 |
Why?
| | Reference Standards | 1 | 2005 | 177 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2006 | 292 | 0.010 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2006 | 190 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 2005 | 114 | 0.010 |
Why?
| | Weight Lifting | 1 | 2004 | 32 | 0.010 |
Why?
| | Dietary Supplements | 1 | 2008 | 576 | 0.010 |
Why?
| | Hydrocortisone | 1 | 2006 | 304 | 0.010 |
Why?
| | Leucine | 1 | 2004 | 116 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3162 | 0.010 |
Why?
| | Patient Discharge | 1 | 2010 | 983 | 0.010 |
Why?
| | Fluorocarbons | 1 | 2005 | 143 | 0.010 |
Why?
| | Chromatography, Liquid | 1 | 2005 | 454 | 0.010 |
Why?
| | Heart Rate | 1 | 2007 | 855 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2006 | 1306 | 0.010 |
Why?
| | Blood Proteins | 1 | 2005 | 249 | 0.010 |
Why?
| | Phosphorylation | 1 | 2006 | 1732 | 0.010 |
Why?
| | Motor Activity | 1 | 2006 | 721 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2005 | 2155 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2930 | 0.010 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2000 | 41 | 0.010 |
Why?
| | Premenopause | 1 | 2000 | 123 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2005 | 2608 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2000 | 2452 | 0.000 |
Why?
|
|
Cree's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|